|
1
|
Hua D, Tang L, Wang W, Tang S, Yu L, Zhou
X, Wang Q, Sun C, Shi C, Luo W, et al: Improved antiglioblastoma
activity and BBB permeability by conjugation of paclitaxel to a
cell-penetrative MMP-2-cleavable peptide. Adv Sci (Weinh).
8(2001960)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lapointe S, Perry A and Butowski NA:
Primary brain tumours in adults. Lancet. 392:432–446.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lin W, Huang Z, Xu Y, Chen X, Chen T, Ye
Y, Ding J, Chen Z, Chen L, Qiu X and Qiu S: A three-lncRNA
signature predicts clinical outcomes in low-grade glioma patients
after radiotherapy. Aging. 12:9188–9204. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bhanja D, Ba D, Tuohy K, Wilding H, Trifoi
M, Padmanaban V, Liu G, Sughrue M, Zacharia B, Leslie D and
Mansouri A: Association of low-grade glioma diagnosis and
management approach with mental health disorders: A MarketScan
analysis 2005-2014. Cancers (Basel). 14(1376)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pallud J, Le Van Quyen M, Bielle F,
Pellegrino C, Varlet P, Cresto N, Baulac M, Duyckaerts C,
Kourdougli N, Chazal G, et al: Cortical GABAergic excitation
contributes to epileptic activities around human glioma. Sci Transl
Med. 6(244ra89)2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Smoll NR, Gautschi OP, Schatlo B, Schaller
K and Weber DC: Relative survival of patients with supratentorial
low-grade gliomas. Neuro Oncol. 14:1062–1069. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mistry M, Zhukova N, Merico D, Rakopoulos
P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN,
et al: BRAF mutation and CDKN2A deletion define a clinically
distinct subgroup of childhood secondary high-grade glioma. J Clin
Oncol. 33:1015–1022. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bell EH, Zhang P, Shaw EG, Buckner JC,
Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ,
et al: Comprehensive genomic analysis in NRG oncology/RTOG 9802: A
phase III trial of radiation versus radiation plus procarbazine,
lomustine (CCNU), and vincristine in high-risk low-grade glioma. J
Clin Oncol. 38:3407–3417. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Reuss DE, Sahm F, Schrimpf D, Wiestler B,
Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt
V, et al: ATRX and IDH1-R132H immunohistochemistry with subsequent
copy number analysis and IDH sequencing as a basis for an
‘integrated’ diagnostic approach for adult astrocytoma,
oligodendroglioma and glioblastoma. Acta Neuropathol. 129:133–146.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lise S, Clarkson Y, Perkins E, Kwasniewska
A, Sadighi Akha E, Schnekenberg RP, Suminaite D, Hope J, Baker I,
Gregory L, et al: Recessive mutations in SPTBN2 implicate β-III
spectrin in both cognitive and motor development. PLoS Genet.
8(e1003074)2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ikeda Y, Dick KA, Weatherspoon MR, Gincel
D, Armbrust KR, Dalton JC, Stevanin G, Dürr A, Zühlke C, Bürk K, et
al: Spectrin mutations cause spinocerebellar ataxia type 5. Nat
Genet. 38:184–190. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Yang Z, Yu G, Guo M, Yu J, Zhang X and
Wang J: CDPath: Cooperative driver pathways discovery using integer
linear programming and Markov clustering. IEEE/ACM Trans Comput
Biol Bioinform. 18:1384–1395. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wu C, Dong B, Huang L, Liu Y, Ye G, Li S
and Qi Y: SPTBN2, a new biomarker of lung adenocarcinoma. Front
Oncol. 11(754290)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Huang M, Long Y, Jin Y, Ya W, Meng D, Qin
T, Su L, Zhou W, Wu J, Huang C and Huang Q: Comprehensive analysis
of the lncRNA-miRNA-mRNA regulatory network for bladder cancer.
Transl Androl Urol. 10:1286–1301. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang P, Liu T, Zhao Z, Wang Z, Liu S and
Yang X: SPTBN2 regulated by miR-424-5p promotes endometrial cancer
progression via CLDN4/PI3K/AKT axis. Cell Death Dis.
7(382)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Feng P, Ge Z, Guo Z, Lin L and Yu Q: A
comprehensive analysis of the downregulation of miRNA-1827 and its
prognostic significance by targeting SPTBN2 and BCL2L1 in ovarian
cancer. Front Mol Biosci. 8(687576)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Riesenberg S, Groetchen A, Siddaway R,
Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans
P, et al: MITF and c-Jun antagonism interconnects melanoma
dedifferentiation with pro-inflammatory cytokine responsiveness and
myeloid cell recruitment. Nat Commun. 6:8755. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Brockmann L, Soukou S, Steglich B,
Czarnewski P, Zhao L, Wende S, Bedke T, Ergen C, Manthey C,
Agalioti T, et al: Molecular and functional heterogeneity of
IL-10-producing CD4+ T cells. Nat Commun.
9(5457)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lyu X, Qiang Y, Zhang B, Xu W, Cui Y and
Ma L: Identification of immuno-infiltrating MAP1A as a
prognosis-related biomarker for bladder cancer and its ceRNA
network construction. Front Oncol. 12(1016542)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gregory AC, Zablocki O, Zayed AA, Howell
A, Bolduc B and Sullivan MB: The gut virome database reveals
age-dependent patterns of virome diversity in the human gut. Cell
Host Microbe. 28:724–740 e8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang Y and Zhu J: Ten genes associated
with MGMT promoter methylation predict the prognosis of patients
with glioma. Oncol Rep. 41:908–916. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14(7)2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15(550)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Uhlen M, Oksvold P, Fagerberg L, Lundberg
E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S,
et al: Towards a knowledge-based human protein atlas. Nat
Biotechnol. 28:1248–1250. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Wen PY and Packer RJ: The 2021 WHO
classification of tumors of the central nervous system: Clinical
implications. Neuro Oncol. 23:1215–1217. 2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
World Health Organization (WHO):
International Classification of Diseases (ICD). WHO, Geneva,
2022.
|
|
30
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Baumert BG, Hegi ME, van den Bent MJ, von
Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn
MJB, Hassel MB, et al: Temozolomide chemotherapy versus
radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): A
randomised, open-label, phase 3 intergroup study. Lancet Oncol.
17:1521–1532. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chatsirisupachai K, Lesluyes T, Paraoan L,
Van Loo P and de Magalhães JP: An integrative analysis of the
age-associated multi-omic landscape across cancers. Nat Commun.
12:2345. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wen JX, Li XQ and Chang Y: Signature gene
identification of cancer occurrence and pattern recognition. J
Comput Biol. 25:907–916. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pignatti F, van den Bent M, Curran D,
Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M,
Vecht C, et al: Prognostic factors for survival in adult patients
with cerebral low-grade glioma. J Clin Oncol. 20:2076–2084.
2002.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yue M, Liu T, Yan G, Luo X and Wang L:
LINC01605, regulated by the EP300-SMYD2 complex, potentiates the
binding between METTL3 and SPTBN2 in colorectal cancer. Cancer Cell
Int. 21(504)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xiao H, Bai J, Yan M, Ji K, Tian W, Liu D,
Ning T, Liu X and Zou J: Discovery of 5-signature predicting
survival of patients with lower-grade glioma. World Neurosurg.
126:e765–e772. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Li Z, Zhu Z, Wang Y, Wang Y, Li W, Wang Z,
Zhou X and Bao Y: has-miR-15a-5p inhibits colon cell carcinoma via
targeting CCND1. Mol Med Rep. 24(735)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Qin S, He NB, Yan HL and Dong Y:
Characterization of microRNA expression profiles in patients with
giant cell tumor. Orthop Surg. 8:212–219. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhang J, Liu H, Hou L, Wang G, Zhang R,
Huang Y, Chen X and Zhu J: Circular RNA_LARP4 inhibits cell
proliferation and invasion of gastric cancer by sponging miR-424-5p
and regulating LATS1 expression. Mol Cancer. 16(151)2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Xu S, Tang L, Liu Z, Luo C and Cheng Q:
Hypoxia-related lncRNA correlates with prognosis and immune
microenvironment in lower-grade glioma. Front Immunol.
12(731048)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Li Y, Gao Y, Niu X, Tang M, Li J, Song B
and Guan X: LncRNA BASP1-AS1 interacts with YBX1 to regulate Notch
transcription and drives the malignancy of melanoma. Cancer Sci.
112:4526–4542. 2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Han X and Zhang S: Role of long non-coding
RNA LINC00641 in cancer. Front Oncol. 11(829137)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yang J, Yu D, Liu X, Changyong E and Yu S:
LINC00641/miR-4262/NRGN axis confines cell proliferation in glioma.
Cancer Biol Ther. 21:758–766. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Liao M, Liao W, Xu N, Li B, Liu F, Zhang
S, Wang Y, Wang S, Zhu Y, Chen D, et al: LncRNA EPB41L4A-AS1
regulates glycolysis and glutaminolysis by mediating nucleolar
translocation of HDAC2. EBioMedicine. 41:200–213. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bin J, Nie S, Tang Z, Kang A, Fu Z, Hu Y,
Liao Q, Xiong W, Zhou Y, Tang Y and Jiang J: Long noncoding RNA
EPB41L4A-AS1 functions as an oncogene by regulating the Rho/ROCK
pathway in colorectal cancer. J Cell Physiol. 236:523–535.
2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cao Y and Aypar U: A novel Xq22.1 deletion
in a male with multiple congenital abnormalities and respiratory
failure. Eur J Med Genet. 59:274–277. 2016.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Petitprez F, Meylan M, de Reyniès A,
Sautès-Fridman C and Fridman WH: The tumor microenvironment in the
response to immune checkpoint blockade therapies. Front Immunol.
11(784)2020.PubMed/NCBI View Article : Google Scholar
|
